These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 19745081)
21. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells. Min H; Xu M; Chen ZR; Zhou JD; Huang M; Zheng K; Zou XP Cancer Chemother Pharmacol; 2014 Jul; 74(1):167-76. PubMed ID: 24842158 [TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Dai Y; Rahmani M; Grant S Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039 [TBL] [Abstract][Full Text] [Related]
23. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Cvek B; Dvorak Z Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411 [TBL] [Abstract][Full Text] [Related]
24. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Oyajobi BO; Garrett IR; Gupta A; Flores A; Esparza J; Muñoz S; Zhao M; Mundy GR Br J Haematol; 2007 Nov; 139(3):434-8. PubMed ID: 17910634 [TBL] [Abstract][Full Text] [Related]
25. Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system. Foti C; Florean C; Pezzutto A; Roncaglia P; Tomasella A; Gustincich S; Brancolini C Mol Cancer Ther; 2009 Nov; 8(11):3140-50. PubMed ID: 19887551 [TBL] [Abstract][Full Text] [Related]
26. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference. Colland F IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381 [No Abstract] [Full Text] [Related]
27. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231 [TBL] [Abstract][Full Text] [Related]
28. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. Pédeboscq S; L'Azou B; Passagne I; De Giorgi F; Ichas F; Pometan JP; Cambar J J Exp Ther Oncol; 2008; 7(2):99-111. PubMed ID: 18771084 [TBL] [Abstract][Full Text] [Related]
29. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. Zou P; Kawada J; Pesnicak L; Cohen JI J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072 [TBL] [Abstract][Full Text] [Related]
30. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072 [TBL] [Abstract][Full Text] [Related]
31. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486 [TBL] [Abstract][Full Text] [Related]
32. Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design. Tan X; Osmulski PA; Gaczynska M Curr Med Chem; 2006; 13(2):155-65. PubMed ID: 16472211 [TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Shapovalov Y; Benavidez D; Zuch D; Eliseev RA Int J Cancer; 2010 Jul; 127(1):67-76. PubMed ID: 19894220 [TBL] [Abstract][Full Text] [Related]
34. Discovery and development of second-generation proteasome inhibitors. Kirk CJ Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543 [TBL] [Abstract][Full Text] [Related]
35. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Perrone G; Hideshima T; Ikeda H; Okawa Y; Calabrese E; Gorgun G; Santo L; Cirstea D; Raje N; Chauhan D; Baccarani M; Cavo M; Anderson KC Leukemia; 2009 Sep; 23(9):1679-86. PubMed ID: 19369963 [TBL] [Abstract][Full Text] [Related]
36. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420 [TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655 [TBL] [Abstract][Full Text] [Related]
38. Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells. Kuhn D; Lam WH; Kazi A; Daniel KG; Song S; Chow LM; Chan TH; Dou QP Front Biosci; 2005 May; 10():1010-23. PubMed ID: 15769601 [TBL] [Abstract][Full Text] [Related]
39. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. Skrott Z; Cvek B Mini Rev Med Chem; 2012 Oct; 12(12):1184-92. PubMed ID: 22931589 [TBL] [Abstract][Full Text] [Related]
40. Effect of noncompetitive proteasome inhibition on bortezomib resistance. Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]